MicroRNA-135b acts as a tumor promoter by targeting the hypoxia-inducible factor pathway in genetically defined mouse model of head and neck squamous cell carcinoma

Cancer Letters

Volumn 331, Issue 2, 2013, Pages 230-238

  Zhang, Lu ^a,b   Sun, Zhi Jun ^a,b   Bian, Yansong ^c   Kulkarni, Ashok B ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b Wuhan University   (China)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Head and neck cancer; Hypoxia; MicroRNA; Mouse model

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; MICRORNA; MICRORNA 135B; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER TISSUE; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; COLONY FORMATION; CONTROLLED STUDY; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; GENE DELETION; HEAD AND NECK NEOPLASMS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MICE; MICE, KNOCKOUT; MICRORNAS; PROTEIN-SERINE-THREONINE KINASES; PTEN PHOSPHOHYDROLASE; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA;

EID: 84875373097     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.01.003     Document Type: Article

References (52)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
2. Leemans C.R., Braakhuis B.J., Brakenhoff R.H. The molecular biology of head and neck cancer. Nat. Rev. Cancer 2011, 11:9-22.
3. Agrawal N., Frederick M.J., Pickering C.R., Bettegowda C., Chang K., Li R.J., Fakhry C., Xie T.X., Zhang J., Wang J., Zhang N., El-Naggar A.K., Jasser S.A., Weinstein J.N., Trevino L., Drummond J.A., Muzny D.M., Wu Y., Wood L.D., Hruban R.H., Westra W.H., Koch W.M., Califano J.A., Gibbs R.A., Sidransky D., Vogelstein B., Velculescu V.E., Papadopoulos N., Wheeler D.A., Kinzler K.W., Myers J.N. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011, 333:1154-1157.
4. Stransky N., Egloff A.M., Tward A.D., Kostic A.D., Cibulskis K., Sivachenko A., Kryukov G.V., Lawrence M.S., Sougnez C., McKenna A., Shefler E., Ramos A.H., Stojanov P., Carter S.L., Voet D., Cortes M.L., Auclair D., Berger M.F., Saksena G., Guiducci C., Onofrio R.C., Parkin M., Romkes M., Weissfeld J.L., Seethala R.R., Wang L., Rangel-Escareno C., Fernandez-Lopez J.C., Hidalgo-Miranda A., Melendez-Zajgla J., Winckler W., Ardlie K., Gabriel S.B., Meyerson M., Lander E.S., Getz G., Golub T.R., Garraway L.A., Grandis J.R. The mutational landscape of head and neck squamous cell carcinoma. Science 2011, 333:1157-1160.
5. White R.A., Malkoski S.P., Wang X.J. TGFbeta signaling in head and neck squamous cell carcinoma. Oncogene 2010, 29:5437-5446.
6. Perez-Sayans M., Suarez-Penaranda J.M., Pilar G.D., Barros-Angueira F., Gandara-Rey J.M., Garcia-Garcia A. Hypoxia-inducible factors in OSCC. Cancer Lett. 2011, 313:1-8.
7. Frese K.K., Tuveson D.A. Maximizing mouse cancer models. Nat. Rev. Cancer 2007, 7:645-658.
8. Lu S.L., Herrington H., Reh D., Weber S., Bornstein S., Wang D., Li A.G., Tang C.F., Siddiqui Y., Nord J., Andersen P., Corless C.L., Wang X.J. Loss of transforming growth factor-beta type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes Dev. 2006, 20:1331-1342.
9. Bian Y., Terse A., Du J., Hall B., Molinolo A., Zhang P., Chen W., Flanders K.C., Gutkind J.S., Wakefield L.M., Kulkarni A.B. Progressive tumor formation in mice with conditional deletion of TGF-beta signaling in head and neck epithelia is associated with activation of the PI3K/Akt pathway. Cancer Res. 2009, 69:5918-5926.
10. Bian Y., Hall B., Sun Z.J., Molinolo A., Chen W., Gutkind J.S., Waes C.V., Kulkarni A.B. Loss of TGF-beta signaling and PTEN promotes head and neck squamous cell carcinoma through cellular senescence evasion and cancer-related inflammation. Oncogene 2012, 31:3322-3332.
11. Sun Z.J., Zhang L., Hall B., Bian Y., Gutkind J.S., Kulkarni A.B. Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model. Clin. Cancer Res. 2012, 18:5304-5313.
12. Kim V.N., Han J., Siomi M.C. Biogenesis of small RNAs in animals. Nat. Rev. Mol. Cell Biol. 2009, 10:126-139.
13. Davis-Dusenbery B.N., Hata A. Mechanisms of control of microRNA biogenesis. J. Biochem. 2010, 148:381-392.
14. Bushati N., Cohen S.M. MicroRNA functions. Annu. Rev. Cell Dev. Biol. 2007, 23:175-205.
15. Winter J., Diederichs S. MicroRNA biogenesis and cancer. Methods Mol. Biol. 2010, 676:3-22.
16. Ruan K., Fang X., Ouyang G. MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer Lett. 2009, 285:116-126.
17. Budhu A., Ji J., Wang X.W. The clinical potential of microRNAs. J. Hematol. Oncol. 2010, 3:37.
18. Garzon R., Marcucci G., Croce C.M. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat. Rev. Drug Discov. 2010, 9:775-789.
19. Garofalo M., Croce C.M. MicroRNAs: master regulators as potential therapeutics in cancer. Annu. Rev. Pharmacol. Toxicol. 2010, 51:25-43.
20. Wang J., Wang Q., Liu H., Hu B., Zhou W., Cheng Y. MicroRNA expression and its implication for the diagnosis and therapeutic strategies of gastric cancer. Cancer Lett. 2010, 297:137-143.
21. Liu X., Chen Z., Yu J., Xia J., Zhou X. MicroRNA profiling and head and neck cancer. Comp. Funct. Genom 2009, 837514.
22. Ramdas L., Giri U., Ashorn C.L., Coombes K.R., El-Naggar A., Ang K.K., Story M.D. MiRNA expression profiles in head and neck squamous cell carcinoma and adjacent normal tissue. Head Neck 2009, 31:642-654.
23. Krichevsky A.M., Gabriely G. MiR-21: a small multi-faceted RNA. J. Cell Mol. Med. 2009, 13:39-53.
24. Liu C.J., Tsai M.M., Hung P.S., Kao S.Y., Liu T.Y., Wu K.J., Chiou S.H., Lin S.C., Chang K.W. MiR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma. Cancer Res. 2010, 70:1635-1644.
25. Bandres E., Cubedo E., Agirre X., Malumbres R., Zarate R., Ramirez N., Abajo A., Navarro A., Moreno I., Monzo M., Garcia-Foncillas J. Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol. Cancer 2006, 5:29.
26. Lowery A.J., Miller N., Devaney A., McNeill R.E., Davoren P.A., Lemetre C., Benes V., Schmidt S., Blake J., Ball G., Kerin M.J. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res. 2009, 11:R27.
27. Sarver A.L., French A.J., Borralho P.M., Thayanithy V., Oberg A.L., Silverstein K.A., Morlan B.W., Riska S.M., Boardman L.A., Cunningham J.M., Subramanian S., Wang L., Smyrk T.C., Rodrigues C.M., Thibodeau S.N., Steer C.J. Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BMC Cancer 2009, 9:401.
28. Ostling P., Leivonen S.K., Aakula A., Kohonen P., Makela R., Hagman Z., Edsjo A., Kangaspeska S., Edgren H., Nicorici D., Bjartell A., Ceder Y., Perala M., Kallioniemi O. Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. Cancer Res. 2011, 71:1956-1967.
29. Nagel R., le Sage C., Diosdado B., van der Waal M., Oude Vrielink J.A., Bolijn A., Meijer G.A., Agami R. Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res. 2008, 68:5795-5802.
30. Necela B.M., Carr J.M., Asmann Y.W., Thompson E.A. Differential expression of microRNAs in tumors from chronically inflamed or genetic (APC(Min/+)) models of colon cancer. PLoS One 2011, 6:e18501.
31. Kawakami K., Kawakami M., Joshi B.H., Puri R.K. Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer. Cancer Res. 2001, 61:6194-6200.
32. Sun Z.J., Chen G., Zhang W., Hu X., Huang C.F., Wang Y.F., Jia J., Zhao Y.F. Mammalian target of rapamycin pathway promotes tumor-induced angiogenesis in adenoid cystic carcinoma: its suppression by isoliquiritigenin through dual activation of c-Jun NH2-terminal kinase and inhibition of extracellular signal-regulated kinase. J. Pharmacol. Exp. Ther. 2010, 334:500-512.
33. Sun Z.J., Chen G., Zhang W., Hu X., Liu Y., Zhou Q., Zhu L.X., Zhao Y.F. Curcumin dually inhibits both mammalian target of rapamycin and nuclear factor-kappaB pathways through a crossed phosphatidylinositol 3-kinase/Akt/IkappaB kinase complex signaling axis in adenoid cystic carcinoma. Mol. Pharmacol. 2011, 79:106-118.
34. Kimura S., Naganuma S., Susuki D., Hirono Y., Yamaguchi A., Fujieda S., Sano K., Itoh H. Expression of microRNAs in squamous cell carcinoma of human head and neck and the esophagus: miR-205 and miR-21 are specific markers for HNSCC and ESCC. Oncol. Rep. 2010, 23:1625-1633.
35. Childs G., Fazzari M., Kung G., Kawachi N., Brandwein-Gensler M., McLemore M., Chen Q., Burk R.D., Smith R.V., Prystowsky M.B., Belbin T.J., Schlecht N.F. Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. Am. J. Pathol. 2009, 174:736-745.
36. Jiang J., Lee E.J., Gusev Y., Schmittgen T.D. Real-time expression profiling of microRNA precursors in human cancer cell lines. Nucleic Acids Res. 2005, 33:5394-5403.
37. Liu X., Yu J., Jiang L., Wang A., Shi F., Ye H., Zhou X. MicroRNA-222 regulates cell invasion by targeting matrix metalloproteinase 1 (MMP1) and manganese superoxide dismutase 2 (SOD2) in tongue squamous cell carcinoma cell lines. Cancer Genom. Proteomics 2009, 6:131-139.
38. Wong T.S., Liu X.B., Wong B.Y., Ng R.W., Yuen A.P., Wei W.I. Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin. Cancer Res. 2008, 14:2588-2592.
39. Li J., Huang H., Sun L., Yang M., Pan C., Chen W., Wu D., Lin Z., Zeng C., Yao Y., Zhang P., Song E. MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin. Cancer Res. 2009, 15:3998-4008.
40. Iliopoulos D., Jaeger S.A., Hirsch H.A., Bulyk M.L., Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol. Cell. 2010, 39:493-506.
41. Xu N., Zhang L., Meisgen F., Harada M., Heilborn J., Homey B., Grander D., Stahle M., Sonkoly E., Pivarcsi A. MicroRNA-125b down-regulates matrix metallopeptidase 13 and inhibits cutaneous squamous cell carcinoma cell proliferation, migration, and invasion. J. Biol. Chem. 2012, 287:29899-29908.
42. Sand M., Skrygan M., Georgas D., Sand D., Hahn S.A., Gambichler T., Altmeyer P., Bechara F.G. Microarray analysis of microRNA expression in cutaneous squamous cell carcinoma. J. Dermatol. Sci. 2012, 68:119-126.
43. Kanaan Z., Rai S.N., Eichenberger M.R., Roberts H., Keskey B., Pan J., Galandiuk S. Plasma miR-21: a potential diagnostic marker of colorectal cancer. Ann. Surg. 2012, 256:544-551.
44. Gaedcke J., Grade M., Camps J., Sokilde R., Kaczkowski B., Schetter A.J., Difilippantonio M.J., Harris C.C., Ghadimi B.M., Moller S., Beissbarth T., Ried T., Litman T. The rectal cancer microRNAome-microRNA expression in rectal cancer and matched normal mucosa. Clin. Cancer Res. 2012, 18:4919-4930.
45. Xu X.M., Qian J.C., Deng Z.L., Cai Z., Tang T., Wang P., Zhang K.H., Cai J.P. Expression of miR-21, miR-31, miR-96 and miR-135b is correlated with the clinical parameters of colorectal cancer. Oncol. Lett. 2012, 4:339-345.
46. Ko M.A., Zehong G., Virtanen C., Guindi M., Waddell T.K., Keshavjee S., Darling G.E. MicroRNA expression profiling of esophageal cancer before and after induction chemoradiotherapy. Ann. Thorac. Surg. 2012, 94:1094-1102.
47. Wilson W.R., Hay M.P. Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 2011, 11:393-410.
48. Wouters B.G., Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat. Rev. Cancer 2008, 8:851-864.
49. Fukuba H., Takahashi T., Jin H.G., Kohriyama T., Matsumoto M. Abundance of aspargynyl-hydroxylase FIH is regulated by Siah-1 under normoxic conditions. Neurosci. Lett. 2008, 433:209-214.
50. Metzen E., Zhou J., Jelkmann W., Fandrey J., Brune B. Nitric oxide impairs normoxic degradation of HIF-1alpha by inhibition of prolyl hydroxylases. Mol. Biol. Cell 2003, 14:3470-3481.
51. Massague J. TGFbeta in Cancer. Cell 2008, 134:215-230.
52. Scapoli L., Palmieri A., Lo Muzio L., Pezzetti F., Rubini C., Girardi A., Farinella F., Mazzotta M., Carinci F. MicroRNA expression profiling of oral carcinoma identifies new markers of tumor progression. Int. J. Immunopathol. Pharmacol. 2011, 23:1229-1234.